Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.
We don't have enough public data on YDES to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.
What is YD Bio Ltd?
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
YDES · Verdict
Moderate reward · moderate risk
YDES stands out on volatility and balance sheet, but watch the cash flow signal.
Based on 75% data coverage
YDES · Verdict
What’s working & what to watch
Strengths 2
Volatility95/100
Top decile vs peers
Balance sheet76/100
Current ratio 13.18
Watchouts 3
Cash flow7/100
-930% free-cash-flow margin
Profitability9/100
-277% net margin · -43% ROE
Valuation41/100
Below average
Model-based scoring. For information only — not financial advice.
What is YD Bio Ltd?
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 605.07M.
Financial Highlights
Investment Breakdown
📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.
Analysis
Reward: Moderate (40)
The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.